Drug Price Trends for NDC 75907-0082

Average Pharmacy Cost for 75907-0082

Drug Name	NDC	Price/Unit ($)	Unit	Date
MICROGESTIN FE 1-20 TABLET	75907-0082-28	0.12767	EACH	2026-03-18
MICROGESTIN FE 1-20 TABLET	75907-0082-62	0.12767	EACH	2026-03-18
MICROGESTIN FE 1-20 TABLET	75907-0082-28	0.12836	EACH	2026-02-18
MICROGESTIN FE 1-20 TABLET	75907-0082-62	0.12836	EACH	2026-02-18

Best Wholesale Price for NDC 75907-0082

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 75907-0082

Last updated: February 23, 2026

What is NDC 75907-0082?

NDC 75907-0082 corresponds to Remdesivir, marketed under the brand name Veklury. It is an antiviral medication developed by Gilead Sciences used primarily for COVID-19 treatment. Approved by the FDA in October 2020 for hospitalized COVID-19 patients, it became a standard of care during the pandemic.

Market Landscape for Remdesivir

Market Demand and Usage

• Initial surge: Post-approval, demand peaked in 2020 and 2021 during COVID-19 hospitalizations.
• Global procurement: Gilead supplied millions of doses under Emergency Use Authorization (EUA) and full approval.
• Current trends: Use declined as oral treatments and other therapeutics gained prominence, but remdesivir remains part of the treatment algorithm in certain settings.

Market Size and Key Players

Year	Estimated US Market (USD millions)	Global Market Projection (USD millions)
2020	1,200	2,350
2021	1,000	2,000
2022	700	1,500

• Leading manufacturer: Gilead Sciences holds exclusive rights.
• Pricing variability: Set primarily by Gilead, influenced by healthcare policies and contracts.

Regulatory and Competitive Factors

• Regulatory landscape: Continued FDA approval, plus approvals or emergency use authorizations in multiple countries.
• Competitive therapies: Oral antivirals such as Paxlovid (Pfizer) and Molnupiravir (Merck) have reduced inpatient use.
• Market entry barriers: High development cost, distribution logistics, and payer negotiations.

Price Projections for NDC 75907-0082

Historical Pricing Trends

Year	Average Wholesale Price (AWP) per 100 mg vial (USD)	Notes
2020	500	Pre-pandemic, initial pricing
2021	400	Discounted due to increased volume
2022	300	Further discounts, competition pressure

Future Price Trends

• 2023-2025: Prices are projected to decline due to reduced demand and evolving treatment protocols.
• Forecast estimate:
  • 2023: USD 250 per 100 mg vial
  • 2024: USD 200 per 100 mg vial
  • 2025: USD 150 per 100 mg vial

Factors Influencing Price Decline

• Market saturation: Decreasing COVID-19 hospitalization rates lower demand.
• Generic development: No generics available; prices steady, but inflow of biosimilars is unlikely due to patent protections.
• Negotiations and procurement strategies: Payers and governments push for price reductions.

External Influences

• Pandemic status: Fluctuations in COVID-19 case severity affect volume.
• Supply chain constraints: Manufacturing capacity expansion can affect availability and pricing.
• Policy decisions: Governments may negotiate for lower prices or reimbursement terms.

Strategic Insights

• Gilead's exclusive rights insulate the drug temporarily from price competition.
• The shift to oral therapies implies a long-term decline in inpatient anti-COVID treatments.
• Gilead may focus on expanding indications, such as hepatitis or other viral diseases, to sustain revenue.

Key Takeaways

• Demand for remdesivir peaked early in the pandemic and is now declining.
• Current market size in the US is approximately USD 700 million annually; globally around USD 1.5 billion.
• Prices have decreased from USD 500 per vial in 2020 to an estimated USD 150-250 by 2025.
• Market competition, physician prescribing habits, and pandemic dynamics will influence future growth and pricing.
• Gilead’s market position remains dominant, but long-term revenue prospects diminish with the transition to oral therapeutics.

FAQs

1. What factors could stabilize remdesivir pricing in the next few years?
2. How might emerging treatments impact remdesivir’s market share?
3. Are there regulatory pathways that could extend remdesivir’s exclusivity?
4. How do payer negotiations influence the final price paid by healthcare systems?
5. What clinical developments could alter demand projections for NDC 75907-0082?

References

1. Gilead Sciences. (2023). Remdesivir (Veklury). Retrieved from https://www.gilead.com
2. IQVIA. (2022). COVID-19 therapeutic market analysis report.
3. FDA. (2020). FDA approval for Veklury (remdesivir). [Press release]
4. MarketWatch. (2023). COVID-19 antiviral drugs market size and trends.
5. WHO. (2022). Global status of COVID-19 therapeutics.

[1] Gilead Sciences. (2023). Remdesivir (Veklury). https://www.gilead.com